References
- Aebi S, Castiglione M (2008). Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19, 14-6.
- Chan KK, Tam KF, Tse KY, Ngan HY (2008). The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol, 110, 158-61. https://doi.org/10.1016/j.ygyno.2008.04.030
- Foley OW, Rauh-Hain JA, del Carmen MG (2013). Recurrent epithelial ovarian cancer: an update on treatment. Oncology, 27, 288-94.
- Fehm T, Heller F, Kramer S, et al (2005). Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res, 25, 1551-4.
- Geurts SM, van Altena AM, de Vegt F, et al (2011). No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study. Int J Gynecol Cancer, 21, 647-53. https://doi.org/10.1097/IGC.0b013e318212b87d
- Geurts SM, de Vegt F, van Altena AM, et al (2011). Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer, 21, 837-45. https://doi.org/10.1097/IGC.0b013e31821bb88c
- Levy T, Weiser R, Boaz M, et al (2013). The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol, 129, 165-8. https://doi.org/10.1016/j.ygyno.2012.12.024
- Menczer J, Chetrit A, Sadetzki S, et al (2006). Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. Gynecol Oncol, 103, 137-40. https://doi.org/10.1016/j.ygyno.2006.02.005
- Miller RE, Rustin GJ (2010). How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol ,22,498-502. https://doi.org/10.1097/CCO.0b013e32833ae8b6
- NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2011. Available from: www.nccn.com
- Rustin GJ, van der Burg ME, Griffin CL, et al (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, 376, 1155-63. https://doi.org/10.1016/S0140-6736(10)61268-8
- Salani R, Backes FJ, Fung MF, et al (2011). Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol, 204, 466-78. https://doi.org/10.1016/j.ajog.2011.03.008
- Tirkes T, Hollar MA, Tann M, et al (2013). Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics, 33, 1323-41. https://doi.org/10.1148/rg.335125214
Cited by
- Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6165
- Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10837
- Outcome of the Gynecologic Oncology Patients Surveillance Network Program vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4901